Clinical Trials
24
Active:14
Completed:7
Trial Phases
4 Phases
Phase 1:6
Phase 2:1
Phase 3:3
+1 more phases
Drug Approvals
2.6k
CANADA:1317
PHILIPPINES:5
SFDA:1
+1 more agencies
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (46.2%)Not Applicable
3 (23.1%)Phase 3
3 (23.1%)Phase 2
1 (7.7%)A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis
Phase 2
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: Dymista™ Nasal SprayDrug: Placebo
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Apotex Inc.
- Target Recruit Count
- 595
- Registration Number
- NCT02279563
A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Apotex Inc.
- Target Recruit Count
- 580
- Registration Number
- NCT02273817
A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Apotex Inc.
- Registration Number
- NCT00987233
- Locations
- 🇺🇸
Clinsys Clinical Research, Inc., Bedminster, New Jersey, United States
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Phase 3
Completed
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2009-03-10
- Lead Sponsor
- Apotex Inc.
- Target Recruit Count
- 497
- Registration Number
- NCT00859105
News
Apotex Launches First Generic Nilotinib in US with 180-Day Market Exclusivity
Apotex Corp. announced the launch of nilotinib capsules, the first generic version of Tasigna® in the United States, with 180 days of market exclusivity.
Formosa Pharmaceuticals and Cipla Form Strategic Partnership for APP13007 Commercialization Across 11 Countries
Formosa Pharmaceuticals has granted Cipla Limited exclusive rights to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries in Asia, Africa, and South America.